Agbonesa, Mark Jay T.
HRN: 21-32-49 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/11/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
05/11/2022
05/17/2022
IVT
115mg
Q8
ALL
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes